摘要
背景：脂肪肝是一种临床常见的疾病,总被认为是个肥胖的代名词而忽略。在台湾,肥胖、糖尿病以及高血脂症的人口越来越多,脂肪肝的发生率呈急剧上升趋势,根据临床统计,台湾非酒精性脂肪肝(nonalcoholic fatty liver disease, NAFLD)的盛行率为40.8%,几乎每三位成年人中就有一位是脂肪肝患者,且部份脂肪肝患者是属于非酒精性脂肪性肝(NAFLD),可能衍生为肝纤维化及肝硬化,甚至是末期肝脏疾病,因此唤起了医界学者对它的注意。
目的：根据中医理论与临床经验,结合现代医学,观察清热化痰祛瘀法对痰热瘀阻型非酒精性脂肪肝患者的临床疗效,并结合肝功、脂质代谢、肾功、血常规等实验室检查及B超等影像学检查,探讨其作用机制及治疗效果。
方法：本研究以台湾地区确诊为非酒精性脂肪肝痰热瘀阻型患者80例进行临床研究,采用随机分配原则,将80例合格对象分为治疗组40例,对照组40例,两组进行基础治疗,治疗组施以自拟方(炒党参10g、柴胡10g、炒白术10g、茯苓10g、瓜萎10g、丹参10g、黄芩10g、垂盆草10g、赤芍10g、白芍10g、泽泻25g、生山楂10g、元胡索10g、地鳖虫10g、水蛭6g)水煎服,一日一剂,分二次服,三个月为一个疗程。对照组施以服用瑞舒伐他汀(Rosuvastatin),1Omg/d,连续三个月。观察指标包括年龄、性别、体重、B超、肝功、脂质代谢及临床症状等方面,比较两组治疗效果。
结果：1.治疗组40例,完全治愈15例(37.5%),显效14例(35.5%),有效5例(12.5%),无效6例(15.0%),总有效率85.0%；对照组40例,完全治愈9例(22.5%),显效9例(22.5%),有效11例(27.5%),无效11例(27.5%),总有效率为72.5%,治疗中、治疗后未见任何不良反应。两组临床综合疗效经P<0.05,两组总体疗效比较,治疗组显著优于对照组。
2.两组治疗后症状总积分比较,有非常显着差异(P<0.01),治疗组非常显著优于对照组。两组均能显著改善各临床症状和体征,差异有显着意义(P<0.05)。治疗组治疗后在食少纳呆、胁痛、疲劳乏力、口干口苦、面色晦暗、胸闷痛、睡眠状况、舌质等症状方面显著优于对照组(P<0.05)。
3.两组治疗后肝功能指标(AST、ALT、ALP、γ-GT),均有非常显着改善(P<0.01)。治疗后两组疗效比较,治疗组显著优于对照组(P<0.05)。
4.两组治疗后脂质代谢指标(TC、TG、HDL-C、LDL-C),均有非常显着改善(P<0.01)。治疗后两组疗效比较,在TG、HDL-C、LDL-C上,治疗组显著优于对照组(p<0.05)。TC两组疗效接近,差异无统计意义(P>0.05)。
结论：治疗组使用自拟方治疗痰热瘀阻型非酒精性脂肪肝患者的临床疗效显著优于对照组。
Background:Fatty liver disease (FLD) is a common clinical disease. it is always ignored as considered as obesity. In Taiwan the population of obesity, diabetes, and hyperlipidemia are gradually increased. The incidence of FLD showed a sharp upward trend. According to clinical statistics, the prevalence of non alcoholic fatty liver disease (NAFLD) patient was40.8%.almost in every three adults have one NAFLD and most of FLD patients are NAFLD, who maybe become liver fibrosis and cirrhosis, even the hepatoma. This symptom also arouse the medical scholars'attention. The disease imputes to Liver、Spleen、Kidney, its formation related to phlegm,dampness,blockage and plot,so we proposed the research of Qing Re Hua Tan Qu Yu method to treat the Tan Re Yu Zu Non-Alcoholic Fatty Liver patients in Taiwan District.
Objective:According to traditional chinese medicine theory and clinical experience, combined with modern medicine.To observe the clinical effect of Qing Re Hua Tan Qu Yu method, and to be combined with liver function, renal function, lipid metabolism, blood routine examination, other laboratory tests and B ultrasound scan, to discuss the function and treatment effect.
Methods:The reserach studies on80NAFLDs who are diagnosed as Tan Re Yu Zu NAFLD,adopted random allocation principle,divided the qualified cases into two groups:one treatment group of40patients, another control group of40patients.Two groups all have the basic treatment.The composition of TCM herbs in treatment group are listed as below:chao-dang-sen10g, chai-hu10g, chao-bai-zhu10g, fu-ling10g, gua-lou10g, dan-senlOg, huang-zin10g, chui-pen-cao10g, chi-shao10g, bai-shao10g, ze-xie10g, sheng-shan-zha10g, uan-hu-suo10g, di-bie-chong10g, shui-zhi6g, boiled with water,one day one package,drink two times per day,one course for3months.The control group:taking the rosuvastatin lOmg/d for3months. The observing indexes include:age, sex, weight, liver function,renal function,lipid metabolism,blood routine examination, B ultrasound scan and clinical symptom score, the differences between two groups has no significant meaning(p>0.05), two groups have comparability.
Results:1. Total effective rate of treatment group is85.0%, the total effective rate of control group is72.5%, both of the two groups have significant difference (p<0.05).It means the effect of treatment group is better than that of control group.
2. After treatment,it has significant differences in clinical symptom score between two groups(p<0.05),the effect of treatment group is better than that of control group. Both of them can improve clinical symptoms obviously,there is a significant difference (p<0.05).The treatment group shows improvement,in chest pain, in listlessness and lassitude, in thirsty and bitter, in gloomy complexion,in chest tightness, in sleep, in tongue and sublingual blue veins, the comparsion has significant meaning (p<0.05).
3. After treatment, both groups in liver function (AST, ALT, ALP, y-GT) have significant difference (p<0.01). The treatment group has better effect than the control group in liver function index (AST, ALT, ALP, r-GT)(P<0.05).
4. After treatment, both groups in lipid metabolism (TC, TG, HDL-C, LDL-C) have significant difference (p<0.01). The treatment group has better effect than the control group in lipid metabolism (TG, HDL-C, LDL-C)(p<0.05). Both groups are closely in effect of TC.
Conclusion:The effect of treatment group in Tan Re Yu Zu NAFLD is better than that of control group.
引文
[1]肃树东.消化病学新理论与新技术[M].上海：上海科技教育出版社,1999.435.
[2]Brunt EM, Janney CG, Di Bisceglie AM, et al.:Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
[3]Ludwig J, Viggiano TR, McGill DB, Oh BJ:Nonalcoholic steatohepatitis:Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-8.
[4]Schaffner F, Thaler H:Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8:283-298.
[5]Day CP, James OFW:Steatohepatitis:a tale of two'hits'? Gastroenterology 1998; 114:842-845.
[6]郝立智,柴国梁：漫谈脂肪肝.台湾医界2004；第47卷第1期：13-17.
[7]谭健民：非酒精性脂肪性肝病的现代观：着重于其衍生“肝纤维化”的致病机转之探讨.台湾医界2008；51卷7期：16-21.
[8]曾民德
[9]Sanyal AJ, American Gastroenterological Association:AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123:1705-25.
[10]Angulo P:Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-31.
[11]Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M:Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27:142-9.
[12]Oshibuchi M, Nishi F, Sato M, et al:Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J Gastroenterol Hepatol 1991; 6; 165-8.
[13]Park SH, Jeon WK, Kim SH et al:Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21:138-43.
[14]Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL:Non-alcoholic fatty liver disease in Malaysia:A demographic, anthropometric, metabolic and histological study. Chin J Dig Dis 2007; 8:58-64.
[15]Wang JT:Hepatitis C virus infection in Taiwan. Gastroenterol J Taiwan 1995; 12:66.
[16]杨逸菊,谢蕙宜,陈振宽,林敏雄：台湾成年人非酒精性脂肪肝相关因子之分析.中华民国家庭医学杂志2000；10卷2期：59-66.
[17]徐瑞宏：脂肪肝.高雄医师会志2000；27：10-11.
[18]赖世伟,廖光福,黄金财：健检民众非酒精性脂肪肝盛行率之分析—以台中市—医学中心为例.辅仁医学期刊2005；3卷2期：75-80.
[19]王丽云,陈荣福,凌美贝,张简吉幸,张玉珍,苏懿：健康检查族群中脂肪肝罹病率及其相关因素之探讨.护理杂志2003；50卷1期：57-64.
[20]叶庆辉,叶淑娟：劳工健检中脂肪肝之相关因素探讨.中华职业医学杂志2004；11卷1期：57-70.
[21]蔡崇煌,李怡庆,罗永杰,周俊德：台湾中部地区某区域医院非酒精性脂肪性肝病与肥胖相关因子之研究.台湾家庭医学杂志2006；16卷4期：215-225.
[22]萧添木,周腾达,沈锰硕,曾嵩智,许诗典,张焕祯,谢泉发：桃园地区电子业员工脂肪肝之盛行率调查.台湾家庭医学杂志 2007；17卷4期：189-198.
[23]黄钧源,黄丽卿,杨俊：台北市65岁以上老人非酒精性脂肪肝相关因素探讨～某一地区医院老人健检资料.台湾老年医学暨老年学杂志2010；5卷1期：62-75.
[24]邵桂霞等：深圳地区28384例体检者体重指数与脂肪肝分布的探讨.[J]中华肝病杂志.2003；(6)：372.
[25]Wanless IR, Lentz JS:Fatty liver hepatitis(steatohepatitis) and obesity:an autopsy study with analysis of risk factors. Hepatology 1990; 12:1106-10.
[26]Kinugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984; 3:408-14.
[27]Friedman LS:Alcoholic & nonalcoholic fatty liver disease. Current Medical Diagnosis & Treatment 2003, 42nd edition. New York, McGraw-Hill,2003; 15:644-645.
[28]Falck-Ytter Y et al:Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis21:17,2001.
[29]Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ:Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-9.
[30]Kumar KS et al:Nonalcoholic steatohepatitis. Mayo Clin Proc 75:733,2000.
[31]Elizabeth M et al.:Nonalcoholic steatohepatitis:Definition and pathology. Semin Liver Dis 21:3,2001.
[32]Marchesini q Brizi M, Bianchi q et al. Nonalcoholic fatter liver disease:a feature of the metabolic syndrome 1 [J] 2. Diabetes,2001,50 (8):4450.
[33]谭健民：糖尿病性脂肪肝形成的机制—亦谈脂肪肝的纤维化.台北市医师公会会刊2007；51：43--46.
[34]Leclercq IA, Farrell GC, Field J, et al.:CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105:1067-1075.
[35]Diehl AM, Li ZP, Lin HZ, et al.:Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54:303-306.
[36]Serin E, Ozer B, Gumurdulu Y, et al.:Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver [J]. J Gast roenterol 2003; 38:471.
[37]范建高
[38]Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121:710-23.
[39]Knobler H, Schattner A, Zhornicki T, et al.:Fatty liver--an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92:73-9.
[40]Hickman IJ, Jonsson JR, Prins JB, et al:Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53:413-9.
[41]Nair S, Diehl AM, Wiseman M, Farr Jr GH, Perrillo RP:Metformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial. Aliment Pharmacol Ther 2004; 20:23-8.
[42]Uygun A, Kadayifci A, Isik AT, et al:Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19:537-44.
[43]McCullough AJ:Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med 2006; 355:2361-3.
[44]Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM:Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129:36-8.
[45]Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR:Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008-17.
[46]Promrat K, Lutchman G, Uwaifo GI, et al:A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188-96.
[47]Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S:Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2485-90.
[48]Yakaryilmaz F, Guliter S, Savas B, et al:Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis:results of a pilot study. Intern Med J 2007; 37:229-35.
[49]Miller III ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E:Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
[50]Dufour JF, Oneta CM, Gonvers JJ, et al:Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-43.
[51]Laurin J, Lindor KD, Crippin JS, et al:Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis:a pilot study. Hepatology 1996; 23:1464-7.
[52]Basaranoglu M, Acbay O, Sonsuz A:A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31:384.
[53]Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P:A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20:623-8.
[1]赖贞志,北市中医会刊[J].2011,54：27-31.
[2]金群.中医分型辨证治疗脂肪肝76例.江苏中医,1997,18(8)：10-12.
[3]姚国科,等。辨证治疗脂肪肝46例。[N]中国医药学报。1995;10(6)；31.
[4]王伯祥.中医肝胆病学[M].北京：中国医药科技出版社,1993：438-445.
[5]畲大德.脂肪肝的诊断和治疗.新中医,1999,31(2)：55-56.
[6]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊断标准[J].中华肝病学杂志,2003,11(2)：71.
[7]林鹤和治疗脂肪肝的经验[J].江西中医药,2000,31(3)：1-2.
[8]司晓晨,陈文垲,卑其新.益肝降脂片治疗脂肪肝34例疗效分析[J].江苏中医,1996,17(7)：8-9.
[9]李伟,等,吉林中医药,1990,(6)：33.
[10]谢锦玉,等,中西医结合杂志,1985,5(8)：487
[11]项平,辽宁中医杂志,1982,(3)：44-.
[12]何基渊,等,北京中医学院学报,1988,11(5)：38.
[13]王开贞,等,中药通报,1986,11(3)：49.
[14]刘寿山,中药研究文献摘要(1820-1961),北京：科学出版社,1963：535.
[15]姜廷良,中医药参考数据,1976,(4)：33.
[16]田明萍,中国民间疗法,2002,(10)：56.
[17]吴春福,中药通报,1985,10(6)：283.
[18]梁旻若,等,新中医,1989,(3)：51
[19]Chang I M,et al.CA,1986,104:124643.
[20]黄国能,中成药研究,1984,(增1)：72.
[21]董晓晖,等,湖北民族学院学报,2003.20(2)：15
[22]王浴生,等。中药药理与应用。北京：人民卫生出版社,1983：3523
[23]北京医学院药学系中药研究小组。北京医学院学报,1959,(1)：1044
[24]“中药十八反”研究协作组。云南中医学院学报,1984,(4)：40
[25]蔡仙德,等,南京铁道医学院学报,1994.13(2)：65.
[26]Kimura Y,et al.Chem Pharm Bull,1982,30(1):219.
[27]胡聪,等,中国中药杂志,2001,26(2)：124.
[28]金国章,等,生理学报,1978,30(1)：67.
[29]邢建峰,等,中国药理学通报,1997,13(3)：258.
[30]徐丽珊,等,浙江师大学报(自然科学版),2001,24(4)：374.
[31]龙子江,等,安徽中医学院学报,1989,8(3)：84.
[32]许俊杰,等,第一军医大学学报,1990,10(3)：262.
[33]王巍,等,中国中药杂志,1991,16(5)：299.
[34]藤多哲郎,等,国外医学·中医中药分册,1984,(5)：303.
[35]范亚明,等,中国动脉硬化杂志,1995,3(2,会议专辑)：157.
[36]谢艳华,等,第四军医大学学报,1997,18(6)：518.
[37]吴钰红,等,上海医科大学学报,1994,21(2)：157.
[38]全小林,等,中国中医药信息,2002,9(6)：21.
[39]周水平,等,中国中医眼科杂志,2002,12(2)：79.
[40]徐文杰,陈建杰,邬文洁.1273例60岁以上老年人非酒精性脂肪肝中医辨证分型初探.亚太传统医药[J].2012,8(1)：58-60.
[41]王利军、杨学峰,中医对脂肪肝的认识及辨证施治[J].中医研究,2002,15(1)：54-55.
142]赵颖、董国华等,健脾消积汤治疗脂肪肝32例,上海中医药杂志(M),2002,1：25.
[43]徐瑛.化痰祛瘀方治疗脂肪肝60例.辽宁中医杂志[M].2001.28(10)：612-613.
[44]张俊智、尚斌、宋爱华.柴胡三合汤治疗肥胖性脂肪肝210例[J].陕西中医学报,2010,(31)9：1170-1171.
[45]邹芷均、孙劲晖.当归芍药散治疗脂肪肝[M].辽宁中医杂志,2006,(33)10：1263-1264.
[46]胡荣听,赵坚敏,朱欲晓,赵素珍,顾庆.复方降脂方治疗脂肪肝60例临床观察.中医导报.2011,17(12)：25-39.
[47]李伏娥等七人.中药穴位透人配合肝病治疗仪治疗脂肪肝的临床研究.中医药学刊,2005,23(6)88-102
[48]黎永生,针灸合用柴胡疏肝散加减治疗脂肪肝30例,陕西中医,2009,30(9),p1207
[49]黎启娇.针灸治疗脂肪肝疗效观察.中国针灸,2004,9(14)：243-244.
[50]钱静娟,华摇忠,刘霞英,徐满琴,张海燕.针灸治疗非酒精性脂肪肝疗效观察与护理.现代中西医结合杂志,2012,21(9)：998-1000.
[51]刘玉,王国顺,田兰军,等·内服外治法治疗脂肪肝的临床研究[J]·中国中西医结合急救杂志,2002,9(5)：299.
[52]王伯祥.中医肝胆病学—匕京：[M]中国医药科技出版社,1993,442
[53]高丽华,张德蕴,丁广谦.降脂保肝丹与洛伐他丁治疗高脂血症性脂肪肝56例.陕西中医[J].2006,26(9)：1097-1098.
[54]单丽娟、刘勇.中西医结合治疗脂肪肝64例临床观察[J].生物磁学,2006,6(1)：
[55]邓银泉、范小芬.脂肪肝中医证型与血生化指标的关系(J).浙江中西医结合杂志,2001,11(3)：138-139.
[56]田立群,胡伟,石拓,张书,时昭红,李桂珍.270例脂肪肝患者中医辨证分型与血脂关系的分析.天津中医药[J]2011,28(6)：463-465.
[1]Brunt EM, Janney CG, Di Bisceglie AM, et al.:Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
[2]Friedman LS:Alcoholic & nonalcoholic fatty liver disease. Current Medical Diagnosis & Treatment 2003, 42nd edition. New York, McGraw-Hill,2003; 15:644-645.
[3]潘桂娟,金香兰,中国医药学报,1994,9(5)：38
[4]姜惟,福建中医药,1990,(3)：15